menu
    • menu
    [{"orgOrder":0,"company":"Ionctura","sponsor":"INKEF Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Series A Financing","leadProduct":"IOA-244","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Ionctura \/ INKEF Capital","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/ INKEF Capital"},{"orgOrder":0,"company":"Ionctura","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"IOA-244","moa":"PI3K","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ionctura \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/ Not Applicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Roginolisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ionctura \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/ Not Applicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Roginolisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ionctura \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/ Not Applicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Roginolisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ionctura \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/ Not Applicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Roginolisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ionctura \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/ Not Applicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Roginolisib","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ionctura \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/ Not Applicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Roginolisib","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ionctura \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/ Not Applicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Roginolisib","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ionctura \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Ionctura \/ Not Applicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Roginolisib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ionctura \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Not Applicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"Syncona Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Small molecule","year":"2024","type":"Series B Financing","leadProduct":"Roginolisib","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ionctura","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Ionctura \/ Syncona Limited","highestDevelopmentStatusID":"9","companyTruncated":"Ionctura \/ Syncona Limited"},{"orgOrder":0,"company":"Ionctura","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Roginolisib","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Ionctura \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ionctura \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Roginolisib

    Menu

    Roginolisib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ionctura

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Ionctura

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Roginolisib,Dostarlimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            iOnctura Announces Expansion of Roginolisib Clinical Trial Program to NSCLC

                            Details : IOA-244 (roginolisib) is a first-in-class small molecule allosteric modulator of PI3Kδ. It is being evaluated for the treatment of non-small cell lung cancer.

                            Brand Name : IOA-244

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 09, 2024

                            Lead Product(s) : Roginolisib,Dostarlimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ionctura

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Ionctura

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Roginolisib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Syncona Limited

                            Deal Size : $85.9 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            iOnctura Announces €80 Million Series B Financing to Progress Pipeline Through Phase II

                            Details : The financing will be used to accelerate the development of IOA-244 (roginolisib), which is being evaluated in the mid-stage clinical trial studies for the treatment of uveal melanoma.

                            Brand Name : IOA-244

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 20, 2024

                            Lead Product(s) : Roginolisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Syncona Limited

                            Deal Size : $85.9 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ionctura

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Ionctura

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Roginolisib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            iOnctura Announces FDA Clearance of IND Application for Roginolisib, a First-in-class Allosteric Modulator of ...

                            Details : IOA-244 (roginolisib) is a first-in-class small molecule allosteric modulator of PI3Kδ. It is being evaluated for the treatment of metastatic uveal melanoma.

                            Brand Name : IOA-244

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 31, 2023

                            Lead Product(s) : Roginolisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ionctura

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Ionctura

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Roginolisib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            iOnctura Awarded UK's MHRA Innovation Passport for Entry Into Innovative Licensing and Access Pathway (ILAP)

                            Details : IOA-244 (roginolisib) is a first-in-class, non-ATP-competitive, allosteric modulator of PI3K delta which prevents tumor proliferation and breaks immune tolerance in patients with solid and hematological tumors.

                            Brand Name : IOA-244

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 28, 2023

                            Lead Product(s) : Roginolisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ionctura

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Ionctura

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Roginolisib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            iOnctura Announces Publication of Pioneering Research Describing the Unique Biological Features of Roginolisib

                            Details : IOA-244 (roginolisib) is a first-in-class, non-ATP-competitive, allosteric modulator of PI3K which prevents tumor proliferation and breaks immune tolerance in patients with solid and hematological tumors.

                            Brand Name : IOA-244

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 16, 2023

                            Lead Product(s) : Roginolisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ionctura

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Ionctura

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Roginolisib,Avelumab,Pemetrexed

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            iOnctura Provides Development Update on First-In-Class Semi-Allosteric PI3Kδ Inhibitor Program

                            Details : IOA-244 is a first-in-class semi-allosteric, non-ATP competitive, small molecule PI3Kδ inhibitor which has shown high beneficial tolerability and clinical benefit profile. PI3Kδ over-expression stimulates multiple cancer mechanisms and an oncogenic rol...

                            Brand Name : IOA-244

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 05, 2023

                            Lead Product(s) : Roginolisib,Avelumab,Pemetrexed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Ionctura

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Ionctura

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Roginolisib,Avelumab,Pemetrexed

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            iOnctura to Present at ASCO Encouraging Phase Ib Refractory Uveal Melanoma Data for First Semi-Allosteric PI3K...

                            Details : IOA-244 is a PI3Kδ specific, orally dosed, small molecule inhibitor that overcomes tumor and stroma induced immune suppression. Its unique chemistry, semi allosteric binding mode and mechanism of action contribute to its unprecedented clinical profile.

                            Brand Name : IOA-244

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 17, 2022

                            Lead Product(s) : Roginolisib,Avelumab,Pemetrexed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Ionctura

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Ionctura

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Roginolisib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            iOnctura Shows No Dose-limiting Toxicity and Reduced T-regs in Solid Tumor Study of PI3K? Inhibitor IOA-244 Pr...

                            Details : Company presenting clinical data on its lead pipeline asset, the PI3K? inhibitor IOA-244, showing no dose-limiting toxicity and a reduction in T regulatory (Treg) cells.

                            Brand Name : IOA-244

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 09, 2021

                            Lead Product(s) : Roginolisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Ionctura

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Ionctura

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Roginolisib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            iOnctura Clinical Expansion Positions Lead PI3Kδ Inhibitor IOA-244 for Potential Registration Studies in Meta...

                            Details : Use of IOA-244 to treat a range of solid tumor types including metastatic uveal melanoma, an underserved cancer with no currently approved drug treatments and poor patient outcomes.

                            Brand Name : IOA-244

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 08, 2021

                            Lead Product(s) : Roginolisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Ionctura

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Ionctura

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Roginolisib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            iOnctura Project Evaluating Novel PI3Kδ-inhibitor IOA-244 in Lymphoma to be Co-Funded by Innosuisse

                            Details : IOA-244 is highly selective for the PI3Kδ isoform and has a novel mechanism of target inhibition, binding the kinase without competing for ATP.

                            Brand Name : IOA-244

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 27, 2021

                            Lead Product(s) : Roginolisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth